Fund Details
Overview
Investment portfolio
34rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
AdvanCell | Jul 2026Participated | $315 MSeries D | |
Fore Biotherapeutics | Jul 2026Led | $67 MSeries D | |
R1 Therapeutics | Mar 2026Participated | $78 MSeries A | |
Jixing Pharmaceuticals | Jan 2026Participated | $287 MSeries D | |
Aeovian Pharmaceuticals | Dec 2025Participated | $55 MSeries B | |
Sanegene Bio | Dec 2025Participated | $110 MSeries B | |
Solve Therapeutics | Nov 2025Participated | $120 MOther Equity | |
Ensoma | Sep 2025Participated | $53 MOther Equity | |
ENTEROME | Jun 2025Participated | $19 MOther Equity | |
Paradox Immunotherapeutics | Feb 2025Led | $10 MOther Equity | |
AdvanCell | Feb 2025Led | $112 MSeries C | |
Metsera | Nov 2024Participated | $215 MSeries B | |
AdvanCell | Jul 2026Participated | $315 MSeries D | |
Fore Biotherapeutics | Jul 2026Led | $67 MSeries D | |
R1 Therapeutics | Mar 2026Participated | $78 MSeries A | |
Jixing Pharmaceuticals | Jan 2026Participated | $287 MSeries D | |
Aeovian Pharmaceuticals | Dec 2025Participated | $55 MSeries B | |
Sanegene Bio | Dec 2025Participated | $110 MSeries B | |
Solve Therapeutics | Nov 2025Participated | $120 MOther Equity | |
Ensoma | Sep 2025Participated | $53 MOther Equity | |
ENTEROME | Jun 2025Participated | $19 MOther Equity | |
Paradox Immunotherapeutics | Feb 2025Led | $10 MOther Equity | |
AdvanCell | Feb 2025Led | $112 MSeries C | |
Metsera | Nov 2024Participated | $215 MSeries B |
34 Items
34
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 0 |
| Series A | 0 | 1 |
| Series B | 2 | 8 |
| Series C+ | 3 | 13 |
| Other Equity | 1 | 5 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| May '19 | 1 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 1 |
| Sep '19 | 1 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 1 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 1 |
| Jul '20 | 0 |
| Aug '20 | 1 |
| Sep '20 | 2 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 1 |
| Mar '21 | 1 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 1 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 1 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 2 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 1 |
| May '23 | 1 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 1 |
| Mar '24 | 2 |
| Apr '24 | 1 |
| May '24 | 1 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 1 |
| Nov '24 | 1 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 2 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 1 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 1 |
| Oct '25 | 0 |
| Nov '25 | 1 |
| Dec '25 | 2 |
| Jan '26 | 1 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 2 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 34 |
| AI & Machine Learning | 3 |
| Professional Services | 3 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 2 |
| $5M-$10M | 0 |
| $10M-$25M | 6 |
| $25M-$50M | 1 |
| $50M-$100M | 12 |
| $100M-$250M | 11 |
| $250M-$500M | 2 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 5 of 5 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 27 |
| Europe | 3 |
| Australia | 2 |
| Canada | 1 |
| China | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Catalio Capital Management | 6 |
| Cormorant Asset Management | 5 |
| Invus | 5 |
| Seventure Partners | 5 |
| T. Rowe Price Associates | 5 |
| Abingworth | 4 |
| Fidelity Management & Research Company | 4 |
| RA Capital Management | 4 |
| Shumway Capital | 4 |
| Viking Global Investors | 4 |
| Alexandria Venture Investments | 3 |
| Ally Bridge Group | 3 |
| ARCH Venture Partners | 3 |
| F-Prime Capital | 3 |
| HBM Healthcare Investments | 3 |
| Khosla Ventures | 3 |
| RTW Investments | 3 |
| 5AM Ventures | 2 |
| Amplitude Ventures | 2 |
| Andera Partners | 2 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 7 | 21% |
| Participating | 27 | 79% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 2 | 29% |
| Co-led | 5 | 71% |
Team
Jahanara Ali
VP of Business Development